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Abstract: Short communication on t(3;21)(q26;q22), with data on clinics, and the genes involved. 
 
Clinics and pathology 
Disease 
Chronic myelogenous leukemia in blast crisis (BC-
CML), myelodysplastic syndrome (MDS) and acute 
myeloid leukemia (AML). 
Note 
Cases of t(3;21)(q26;q22) are mostly treatment-related 
blast crises of CML, and treatment-related 
MDS/AMLs. However, the t(3;21) may also be found 
in rare instances of CML prior to the onset of blast 
crisis (Coyle and Najfeld, 1988). 
In selected publications (Sacchi et al., 1994; Secker-
Walker et al., 1995; Jeandidier et al., 2006; Poppe et 
al., 2006; Yin et al., 2006; see below), there were equal 
numbers of BC-CML cases and MDS/AML cases (53% 
and 47% respectively, out of 60 cases). A very few 
cases of chronic myeloproliferative disease without a 
t(9;22) have been documented (3,4% of the 146 cases 
of t(3;21) collected in the Mitelman database). Most 
cases of AML are M2-AML or M4-AML (+ two cases 
of M5b, one M6, one M7). MDS cases are mostly 
refractory anemia with excess of blasts (RAEB, also 
including RAEB-1 and RAEB-2) (+ one case of 
refractory anemia, one case of chronic myelomonocytic 
leukemia). 
Cases of t(3;21) herein reviewed were selected and 
pooled together from the large studies (Lafage-
Pochitaloff-Huvalé et al., 1989; Rubin et al., 1990; 
Sacchi et al., 1994; Secker-Walker et al., 1995; 
Jeandidier et al., 2006; Poppe et al., 2006; Lugthart  
et al., 2010; Paquette et al., 2011); BC-CML cases and 
MDS/AML cases were separated into two distinct 
entities for further studies; each entity was then 
compared with the equivalent entities from the largest 
study (Yin et al., 2006), and, in the occurence where 
there was no discrepancy, all the cases in each entity 
(BC-CML and MDS/AML) were again pooled 
together.  
As a matter of fact, the only discrepancy was the sex 
ratio in MDS/AML entity: 55% male / 45% female 
patients in the 29 cases from the "large studies" vs 30% 
male / 70% female patients in the 10 cases from the 
"largest study".  
In the review herein below, we therefore study a 
sample of 42 cases of BC-CML, and 39 cases of 
MDS/AML. In some instances, the whole sample of 
cases of t(3;21) harvested in the Mitelman database was 
taken into account (146 cases). 
Etiology 
Rubin et al., 1990 noted that t(3;21) represents 3,6% of 
therapy related MDS/AMLs (t-MDS/AML); they did 
not find one case of t(3;21) amongst 1500 de novo 
MDS/AMLs. 
Yin et al., 2006 noted that 15 of their 16 BC-CML 
patients had previously been treated with hydroxyurea, 
before blast crisis.  
The occurrence of the t(3;21) heralded blast 
transformation.  
The authors conclude that prior treatment with 
hydroxyurea or other antimetabolites (fludarabine, 5-
fluorouracil) are implicated in t(3;21) malignant blood 
diseases.  
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t(3;21)(q26;q22). Left: G-banding - Top - Courtesy Marian Stevens-Kroef; Middle three: Courtesy Steven Richebourg; Center: R-banding 
- Top: Courtesy Peter Vandenberghe; Middle three: Courtesy Olivier Theisen; Bottom two: Courtesy Christine Perot; Right: FISH with 
EVI1 break apart probe Courtesy Olivier Theisen. 
 
 
Paquette et al., 2011, report that MECOM (also known 
as EVI1) translocations were seen in 12% of BC-CML 
before tyrosine kinase inhibitors treatments, a 
percentage reaching 35-40% with current treatments.  
The authors note that BCR-ABL1 and MECOM 
collaborate in leukemogenesis in animal models. 
Coexistence of BCR-ABL1 and MECOM translocation 
is sufficient to cause evolution towards BC-CML.  
The interval between the diagnosis of the initial 
neoplasm and the occurrence of the t(3;21) was 24 
months (median, range 3-154 months) in CML-->BC-
CML, and 38 months (median, range 6-144 months) for 
MDS/AML cases (Yin et al., 2006). 
In our meta-analysis, 81% of 33 cases of BC-CML and 
87% of 31 cases of MDS/AML can be considered to be 
secondary to previous treatment. 
Results presented herein can be compared with those of 
a study from an International Workshop on treatment 
related leukemia: "t(3;21)(q26;q22) in  
 
 
treatment related leukemia". 
Epidemiology 
Translocation t(3;21) represents 0,14% of AML cases 
and 3% of 3q abnormalities cases (9 cases out of 6515 
AML patients) in Lugthart et al., 2010. 
Median age was 58 years (range 21-77) in BC-CML 
(n=42), and around 65 years (range 13-76, only one 
child) in MDS/AML (n=39). 
From 146 cases extracted from the Mitelman database, 
sex ratio was 1,44 (59% male and 41% female 
patients). In the 42 cases of BC-CML herein selected 
for study, there was 71% male and 29% female patients 
(p<0.01).  
In the 39 cases of MDS/AML, no conclusion can be 
drawn, owing to conflictory data between "large 
studies" and "the largest study" (see above); the oddity 
of pooling heterogenous samples would result, in the 
present case, in a balanced sex ratio (19M/20F), but, 
again this is nonsense and the issue rewards further 
studies. 
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Cytology 
Secker-Walker et al., 1995 noted low platelet counts, 
dysmyelopoiesis, decreased number of 
megakaryocytes, and micromegakaryocytes in 
MDS/AML cases; micromegakaryocytes were also 
seen in BC-CML cases (Yin et al., 2006). 
Prognosis 
Poor survival (see figure above). Median survival is 4 
months (range 0-21 months, n=18) in the MDS/AML 
group, and 9 months (range 1-79+ months, n=30 cases, 
reports from 1995 to 2011) in the BC-CML group.  
Median survival was 13 months in the most recent 
cases of BC-CML (n= 20 cases) (Yin et al., 2006; 
Paquette et al., 2011). 
Genetics 
Note 
In a study of cases with 3q21 and/or 3q26 
abnormalities (Lugthart et al., 2010), no mutation of 
FLT3-TKD (tyrosine kinase domain), NPM1, CEBPA, 
KIT, MLL-PTD (partial tandem duplication), K-RAS 
were found in the t(3;21)(q26;q22) cases; in the whole 
3q26 group (inv(3)/t(3;3) excluded), there were 11% of 
FLT3-ITD (internal tandem duplication) and 25% of N-
RAS mutation. 
Cytogenetics 
Cytogenetics morphological 
From the 146 cases extracted from the Mitelman 
database, the t(3;21) was the sole anomaly in 25% of 
cases, accompanied with a t(9;22)(q34;q11) in 40%, 
with -7/del(7q) in 15%, +8 in 11%, +12 in 5%, del(5q) 
in 3%, and +9, +13, or del(20q) in 1% each.  
Again from these 146 cases, when the t(3;21) was the 
sole anomaly, the diagnosis was AML in 84% of cases, 
and MDS in 14%; in cases with a -7/del(7q), the 
diagnosis was AML in 64% of cases, MDS in 18%, and 
CML in 14%; in cases with a +8, the diagnosis was 
CML in two third of cases, and AML in 25%; in cases 
with a +12, the diagnosis was CML in half of the cases, 
and AML in the other half. 
In the BC-CML series (with a t(9;22), indeed), the 
t(3;21) was accompanied with +8 in 16% of cases, +12 
in 5%, and with -7/del(7q) or -5/del(5q) in 3% each. 
The profile in MDS/AML cases is here very different: 
the t(3;21) was the sole anomaly in 36% of cases, 
accompanied with -7/del(7q) in 26%, +8 in 8%, del(5q) 
or del(20q) in 5% each, +12 in 3%. A complex 
karyotype may be present. 
Genes involved and proteins 
MECOM 
Location 
3q26 
Note 
MECOM is also known as EVI1 or PRDM3; MECOM 
symbol means: "MDS1 and EVI1 complex locus". 
Protein 
"EVI1" contains two domains of seven and three zinc 
finger motifs, respectively, a repression domain 
between the two sets of zinc fingers, and an acidic 
domain at its C-term.  
Sequence specific DNA binding protein.  
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Interacts with transcriptional coactivators, corepressors, 
and other sequence specific transcription factors. 
MECOM ("MDS1-EVI1") also contains a PR domain 
from "MDS1" in N-term (Wieser, 2008). 
RUNX1 
Location 
21q22 
Note 
RUNX1 has also been known as AML1 or CBFA2. 
DNA/RNA 
Transcription is from telomere to centromere. 
Protein 
Contains a Runt domain and, in the C-term, a 
transactivation domain, an inhibition domain, and 
various regulatory regions; forms heterodimers; widely 
expressed; nuclear localisation; transcription factor 
(activator) for various hematopoietic-specific genes. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Note 
Breakpoint after exon 5 or 6 in RUNX1. Breakpoints 
are variable and dispersed along EVI1, MDS1 and the 
telomeric region of these two genes (Poppe et al., 
2006). 
Description 
Fusion gene: on the der(3); 5' RUNX1 - 3' MECOM. 
Fusion protein 
Description 
RUNX1/MECOM: 180 kDa. The translocation protein 
includes the N-term RUNX1 with the Runt domain and 
most of the gene MECOM, from the second 
untranslated exon of EVI1 to C-term, which includes 
the 2 zinc finger motifs, the repression domain, and the 
acidic domain, or also including the MDS1 PR domain 
followed by EVI1 domains as noted above. 
Oncogenesis 
Inappropriate and ectopic expression of MECOM 
(either as EVI1 or as MDS1-EVI1) (Poppe et al., 2006; 
Lugthart et al., 2010); interferes with RUNX1 functions 
in a dominant negative manner. 
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